4.8 Article

Structural and mechanistic insights into the Artemis endonuclease and strategies for its inhibition

Journal

NUCLEIC ACIDS RESEARCH
Volume 49, Issue 16, Pages 9310-9326

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/nar/gkab693

Keywords

-

Funding

  1. Cancer Research UK Programme Award [A24759]
  2. Wellcome Trust [106169/ZZ14/Z, 106244/Z/14/Z]
  3. Wellcome
  4. CRUK
  5. Wellcome Trust [106244/Z/14/Z] Funding Source: Wellcome Trust

Ask authors/readers for more resources

Artemis is an endonuclease that plays a key role in the development of B- and T-lymphocytes and in the repair of dsDNA breaks by non-homologous end-joining. Artemis has predominantly endonuclease activity, which is different from its closely related SNM1A and SNM1B nucleases that have predominantly exonuclease activity.
Artemis (SNM1C/DCLRE1C) is an endonuclease that plays a key role in development of B- and Tlymphocytes and in dsDNA break repair by non-homologous end-joining (NHEJ). Artemis is phosphorylated by DNA-PKcs and acts to open DNA hairpin intermediates generated during V(D)J and classswitch recombination. Artemis deficiency leads to congenital radiosensitive severe acquired immune deficiency (RS-SCID). Artemis belongs to a superfamily of nucleases containing metallo-beta-lactamase (MBL) and beta-CASP (CPSF-Artemis-SNM1-Pso2) domains. We present crystal structures of the catalytic domain of wildtype and variant forms of Artemis, including one causing RS-SCID Omenn syndrome. The catalytic domain of the Artemis has similar endonuclease activity to the phosphorylated full-length protein. Our structures help explain the predominantly endonucleolytic activity of Artemis, which contrasts with the predominantly exonuclease activity of the closely related SNM1A and SNM1B MBL fold nucleases. The structures reveal a second metal binding site in its beta-CASP domain unique to Artemis, which is amenable to inhibition by compounds including ebselen. By combining our structural data with that from a recently reported Artemis structure, we were able model the interaction of Artemis with DNA substrates. The structures, including one of Artemis with the cephalosporin ceftriaxone, will help enable the rational development of selective SNM1 nuclease inhibitors.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available